- Revealing the differences between CEE & CIS and the benefits of clinical trials in CEE with Jiri Kopriva, Head of Medical Affairs at Janssen-Cilag, Czech Republic
- Moldovan Perspectives on Regulatory Concerns with Clinical Trials with Lucia Turcan, Head of Drug Evaluation-Authorization Department at the Medicines Agency of Moldova
- Overview of Conducting Clinical Trials in the Russian Federation
- Ukraine – Assessment of the Progress in the Recent Years
- and much more!
With the increasing demand for eligible study patient populations as well as the need for more cost-efficient clinical development programs, the CEE and CIS region represents an attractive location for pharma companies to conduct clinical trials.
However, there are a number of challenges that all industry stakeholders need to overcome in order to conduct clinically and commercially successful trials. Fleming Europe once again invites you to attend two days of ground-breaking discussion and pioneering case-studies from top pharma industry, regulatory and clinical experts at the 5th Annual CEE & CIS Clinical Trials Forum. We will be discussing key issues such as: